CMMB 8-K/A
Chemomab Therapeutics Ltd. (CMMB)
8-K/A
2022-11-29
For: 2022-11-14
View Original
Added on
April 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2022 (
(Exact name of Registrant as Specified in Its Charter)
| State of |
||
| (State or Other Jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
||
| * |
* Not for trading; only in connection with the registration of American Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
EXPLANATORY NOTE
This Form 8-K/A is being filed as an amendment (the “Amendment”) to the Current Report on Form 8-K filed with the Securities and
Exchange Commission on November 14, 2022 (“Original Filing”). The sole purpose of this Amendment is to furnish Exhibit 10.1, which was inadvertently omitted in the Original Filing as a result of a clerical error. Other than as described above,
this Amendment does not modify or update any disclosures in or exhibits to the Original Filing nor does it reflect any events that may have occurred subsequent to the Original Filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
|
(d)
|
Exhibits
|
|
Exhibit
No. |
|
Description
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
CHEMOMAB THERAPEUTICS LTD.
|
|
|
|
|
|
|
|
|
Date: November 28, 2022
|
By:
|
/s/ Donald Marvin
|
|
|
|
|
Name: Donald Marvin
|
|
|
|
|
Title: Executive V.P., Chief Financial Officer
and Chief Operating Officer
|
|
Exhibit 10.1
Chemomab Therapeutics, Ltd.
Kiryat Atidim, Building 7
Tele Aviv, Israel 6158002
Date: October 10, 2022
Matt Frankel
672 Prospect Avenue
Princeton, New Jersey 08540
Dear Matt:
Chemomab Therapeutics, Inc. (the “Company”) is pleased to offer you employment as Chief Medical Officer & VP, Drug Development on the
following terms:
1. Position; Effective Date. You will report to the Chairman & Chief Executive Officer and will perform the duties
customarily associated with this position, and such other duties assigned by the Company. You shall devote your full time and attention to the business affairs of the Company. This agreement shall be effective and your employment with the
Company shall commence on a date mutually acceptable to you and the Company. The date you actually commence working for the Company, is referred to as your “Start Date.” Your Start Date will be November 14, 2022. Your employment is contingent upon the verification of information within the background check process as well as the reference feedback received.
2. Compensation and Benefits.
Base Salary. Beginning on your
Start Date, your annual base salary will be $450,000 less payroll deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. Your regular base salary will not accrue prior to your Start Date.
Performance Bonus. Each calendar
year, you will be eligible to earn an additional cash bonus with a target bonus of up to 45% of base salary, based on the Board’s assessment of employee’s individual performance and overall, Company performance. In order to earn and receive the
bonus, the employee must remain employed by the Company through and including the bonus payout date, which will be on or before March 15 of the year following the year for which it is paid. The determination of whether the employee has earned a
bonus and the amount thereof shall be determined by the Board (and/or a committee thereof) in its sole and absolute discretion. The Company reserves the right to modify the bonus criteria and targets from year to year. Since you are commencing
your employment after October 1st, you will not be eligible for a 2022 performance bonus.
Special Milestone Bonuses. You
will be eligible for special bonuses of $200,000. On the first payroll following 60 days of employment, you will earn a one-time bonus of
$100,000, less applicable withholdings (the “Start Bonus”). The Company will pay you that Special Start Bonus within sixty (60) days after your start date with the Company (the “Start Date”). You will also be eligible to earn a second special bonus
of $100,000. The Company will pay you this “Second Special Bonus” within one hundred twenty (120) days of employment. You must be employed by Chemomab to be eligible for either bonus payment.
Stock Options. Time-Based Stock Option Grant. Subject to the approval of the Parent Board, the Employee will be granted an option to purchase up to 125,000 ADSs (the “Time-Based
Option Shares”). This option will vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remainder in equal amounts over the next 36 monthly periods. This option will be governed by the terms of the
Parent’s 2017 Share Incentive Plan as amended from time to time (the “Plan”), and any award agreement thereunder.
Employee Benefits. You shall be
entitled to all benefits for which you are eligible under the terms and conditions of the standard Company benefit plans at such time as such benefits are provided by the Company to its employees generally.
3. Other Activities During Employment.
Activities. Except with the prior
written consent of the Company, you will not during your employment undertake or engage in any other employment, occupation, or business enterprise without written agreement by the company. I may engage in civic and not-for-profit activities, so
long as such activities do not interfere with the performance of my job duties.
Investment and Interests. Except
as otherwise permitted by the Confidentiality Agreement (as defined below), during your employment you agree not to acquire, assume, or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or
antagonistic to the Company, or its business or prospects, financial or otherwise.
4. Company Policies; Employee Confidential Information and Inventions Agreement. You agree to execute, or have previously
executed, the Company’s Employee Confidential Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A
(the “Confidentiality Agreement”). You further agree to abide by the Company’s rules, policies, and procedures.
5. At-Will Employment Relationship. Employment with the Company is for no specific period of time. Your employment with the
Company will be on an “at will” basis, meaning that either you or the Company may terminate your employment at any time for any reason or no reason, without further obligation or liability. Although your job duties, title, compensation, and
benefits, as well as the Company’s personnel policies and procedures, may change from time to time, this policy of at-will employment is the entire agreement as to the duration of your employment and may only be modified in an express
written agreement signed by you and the Company.
6. General Provisions.
Severability. Whenever possible,
each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such
jurisdiction so as to render it valid, legal, and enforceable consistent with the intent of the parties insofar as possible.
Entire Agreement. This Agreement,
together with its exhibits, constitutes the entire and exclusive agreement between you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between you and the Company with regard to
this subject matter. It is entered into without reliance on any promise, representation, statement, or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended except in a writing signed by you and
a duly authorized officer of the Company.
Successors and Assigns. This
Agreement is intended to bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors, and administrators, except that you may not assign any of your duties hereunder and
you may not assign any of your rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. Furthermore, it shall be considered a material breach of this agreement if the Company does not obtain assumption
of this agreement by any successor to the Company.
Governing Law. All questions
concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of New York.
Arbitration. Any and all
controversies, claims or disputes between you and the Company (including any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from your
employment with Company or the termination of your employment with Company shall be submitted to and settled by binding arbitration in New York State, in accordance with the Employment Dispute Resolution Rules then in effect of the American
Arbitration Association (the “AAA Rules”). Arbitration will be conducted by one arbitrator, mutually selected by you and the
Company. The final decision of the arbitrator(s) shall be furnished to you and the Company in writing and shall constitute a conclusive determination of the issue(s) in question, binding upon you and the Company and shall not be contested by either
you or the Company. You acknowledge and agree that you are agreeing to arbitrate disputes voluntarily and without any duress or undue influence by the Company or anyone else. You further acknowledge and agree that you have carefully read these
terms and that you have asked any questions needed for you to understand the terms, consequences and binding effect of this agreement and fully understand it, including that you are waiving your right to a jury trial. Finally, you agree that you
have been provided an opportunity to seek the advice of an attorney of your choice before signing up to these terms.
Execution. This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic
Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.
[Signature page follows]
Please sign and date this letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return
them to Sarajane Mackenzie by October 17, 2022, if you wish to accept employment at the Company under the terms described above.
We look forward to your favorable reply and to a productive and enjoyable work relationship.
|
|
|
Very truly yours,
Chemomab Therapeutics, Ltd.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Dale R. Pfost |
|
|
|
|
Name: Dale R. Pfost
Title: Chairman & CEO
|
|
|
|
|
|
|
|
|
|
ACCEPTED AND AGREED:
Matthew Frankel
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Matthew Frankel
|
|
|
|
|
|
Signature
|
|
|
|
|
|
|
|
|
|
|
|
10/11/2022
|
|
|
|
|
|
Date
|
|
|
|
|
Exhibit A – Employee Confidential Information and
Inventions Assignment Agreement
Exhibit A
Employee Confidential Information and Inventions Assignment Agreement